NEW YORK–(BUSINESS WIRE)–BTIG announced today that its 3rd Annual Ophthalmology Day will take place on Monday, November 27, 2023. The virtual, one-day event will include thematic panel discussions, one-on-one meetings and company presentations. The event will be hosted by:
“Now in our 3rd year, the BTIG Ophthalmology Day brings together ophthalmic companies across medical devices, diagnostics, therapeutics, and digital health to showcase the latest innovations and trends in the ophthalmic space,” commented Mr. Zimmerman. “BTIG’s emphasis on Ophthalmology is a testament to the depth and sector expertise offered to institutional investors who have growing interest in these attractive market areas.”
More than 30 public and private medical technology and biotechnology companies will be participating in BTIG’s event this month. Panel discussion topics will include exploring the latest developments and trends within ophthalmic medical technologies and therapeutics.
For more information about the event, email uscorporateaccess@btig.com. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a firm representative or log in to www.btigresearch.com.
BTIG’s 3rd Annual Ophthalmology Day is being produced by BTIG’s Corporate Access program which hosts client events across the consumer, energy and infrastructure, financials, healthcare, real estate as well as technology, media, and telecommunications sectors.
About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 20 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities. The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.
Disclaimer: https://www.btig.com/disclaimer.aspx
Contacts
Media: Bailey Burrows
646.818.9092
bburrows@prosek.com
Vanessa Siderow
212.738.6148
vsiderow@btig.com
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…